The incidence of fibrosis, a normal part of wound healing, but also, under persistent inflammation or injury, a disease process that contributes to organ damage, has been steadily increasing over the past decade. This could be partly due to the percentage of elderly and thus chronic disease and inflammation rising in the population. Activity in the drug development arena for fibrosis has also grown. Much of the progress has been spurred by the fields of autoimmunity and inflammation which are revealing common mechanisms for fibrosis across the organs where fibrosis is most frequently observed: lung, liver, heart, kidney and skin. The approval of two drugs for a form of lung fibrosis, idiopathic fibrosis (IPF), has also accelerated progress in the field. However it is likely that multiple therapeutic approaches for treating fibrosis will be necessary because of the many contributors to the condition. For this reason, CHI’s Inaugural Targeting Fibrosis conference aims to convene the leading fibrosis researchers from academics and industry working across organ types, as well as immunology and inflammation investigators to share progress and shape future directions in this burgeoning field of new drug discovery.
Integrins as Fibrosis Targets
Targeting Integrins for Fibrotic Diseases
Liangsu Wang, PhD, Vice President, Head of Biology, Morphic Therapeutic
Targeting Integrins for Fibrosis: Updates on Drug Leads and Candidates
Ji Zhang, PhD, Scientist, Cardiometabolic & Fibrosis Drug Discovery, Merck Research Labs
IDL-2965: A Selective, Highly Potent, Clinical-Stage, Oral Integrin Antagonist for Treatment of Chronic Fibrosis
Karl Kossen, PhD, Senior Vice President, Translational Science, Indalo Therapeutics
Established and Emerging Integrin Targets and Treatments for Fibrosis
Scott Turner, PhD, Vice President, Translational Sciences, Pliant Therapeutics
Emerging Fibrosis Targets (Non-Integrins)
Lysyl Oxidase and Lysyl Oxidase-Like Inhibitors for the Direct Treatment of Fibrosis
Jonathan Foot, PhD, Senior Research Scientist, Drug Discovery, Pharmaxis Ltd.
Discovery and Development of NTZ as an Anti-Fibrotic Agent in NASH
Suneil Hosmane, PhD, Executive Vice President, Strategic Development, Genfit
Cell Senescence and Senolytic Strategies in IPF
Cory M. Hogaboam, PhD, Professor, Department of Medicine, Cedars-Sinai Medical Center
Challenges in Anti-Fibrotic Drug Development
Developing Translational Tools for the Development of Anti-Fibrotic Therapies
Melanie Ruzek, PhD, Principal Scientist, Translational Immunology, Abbvie
Talk Title to be Announced
Brad Geddes, PhD, Senior Director, Innate Immunity Research Unit, GSK
* The program is subject to change without notice, due to unforeseen reason.